Does pegylated liposomal doxorubicin improve outcomes compared to continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia?
In elderly patients with acute lymphoblastic leukemia, pegylated liposomal doxorubicin did not improve outcomes compared to continuous-infusion doxorubicin, although it was associated with reduced toxicities.
With the drug schedules used in this study, pegylated liposomal doxorubicin did not improve the outcome of elderly patients with acute lymphoblastic leukemia despite reduced toxicities.
Hunault et al. (Fri,) studied this question.